Celltrion Pharm
CompanySouth Korea
Celltrion Pharm develops 2 assets, the furthest in phase 3 (Ezetimibe/Rosuvastatin in hypercholesterolemia). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and NPC1L1; based in South Korea.
- Assets
- 2
- Furthest
- Phase 3
- Trials
- 2
- Signals
- 0
Pipeline
2Dual inhibition of intestinal cholesterol absorption via NPC1L1 and hepatic cholesterol synthesis via HMGCR.
Phase 3Small moleculeLipid and ceramide metabolismHMGCRhypercholesterolemiahypertension
Dual inhibition of intestinal cholesterol absorption via NPC1L1 and hepatic cholesterol synthesis via HMGCR.
Phase 3Small moleculeLipid and ceramide metabolismHMGCRhypercholesterolemiahypertension
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials2
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 9 sources